Tumor vascular infarction: prospects and challenges.

Area of Science:

• Oncology
• Vascular Biology
• Biotechnology

Background:

• Tumor vascular infarction induces thrombosis to occlude tumor vasculature, leading to ischemia and necrosis.
• This strategy, pioneered by Huang et al., aims to selectively target tumor neovasculature.
• Coaguligands, like truncated human tissue factor (tTF) fused with targeting moieties, are developed for this purpose.

Purpose of the Study:

• To review the clinical significance, advantages, and disadvantages of tumor vascular infarction.
• To highlight the limitations of current coaguligand approaches, such as leaky thrombosis induction.
• To propose a novel strategy for enhancing the clinical translation of tumor vascular infarction.

Main Methods:

• Review of existing literature on tumor vascular infarction and coaguligands.
• Comparison of tumor vascular infarction with angiogenesis inhibitors and vascular disrupting agents.
• Analysis of the clinical application and limitations of tTF-NGR.

Main Results:

• Tumor vascular infarction demonstrates long-term curative potential in preclinical models (mice).
• tTF-NGR is the sole clinically tested coaguligand, despite limitations in thrombosis induction.
• Current approaches face challenges in achieving selective and efficient thrombosis within tumor vasculature.

Conclusions:

• Tumor vascular infarction is a promising cancer therapy with significant curative potential.
• Improving the precision and efficacy of thrombosis induction is crucial for clinical translation.
• Novel strategies are needed to overcome the limitations of current coaguligand-based approaches.